Excerpt from the 2023 American Association for the Study of Liver Diseases practice guideline: prevention, diagnosis, and treatment of hepatocellular carcinoma
10.3760/cma.j.cn501113-20231107-00181
- VernacularTitle:《2023年美国肝病学会实践指南：肝细胞癌预防、诊断和治疗》要点摘译
- Author:
Zhengyu WANG
1
;
Dongdong XIA
;
Guohong HAN
Author Information
1. 西安国际医学中心医院消化与外周血管介入科，西安 710100
- Keywords:
Hepatocellular carcinoma;
Guidelines;
Management;
Screening;
Therapy
- From:
Chinese Journal of Hepatology
2023;31(12):1262-1265
- CountryChina
- Language:Chinese
-
Abstract:
The 2023 American Association for the Study of Liver Diseases practice guidelines (hereinafter referred to as the Guidelines) provide the latest approach for the prevention, diagnosis, and treatment of hepatocellular carcinoma. The prior American Association for the study of Liver Diseases (AASLD) HCC guidelines have been updated to reflect the clinically significant advances in multiple fields of HCC. Notable examples of these updates include recommendations for the use of ultrasound and alpha-fetoprotein for HCC monitoring, the expansion of surgical treatment indications, the addition of immunosuppressive therapy as first-line systemic therapy, and the implementation of clear multidisciplinary care and proactive care planning.
